• News
  • Stock Screener
  • Small Caps
  • Guru Portfolios
  • Review
  • News
  • Stock Screener
  • Small Caps
  • Guru Portfolios
  • Review
  • X (Twitter)
  • LinkedIn
Stock Screener·India·Healthcare·PGHL.NS
Share

Procter & Gamble Health Limited Stocks

₹ 5015Last Updated 23.10.2026

Issuer Rating

5/7
Performance

Strong

Risk

Moderate

Recommendation

Hold

Market Cap

₹ 908.92M

₹ 5015
Key Takeaways

Risk factor

Poor trading liquidity

Data is available to registered users only
Data is available to registered users only

Profitability factor

Very strong margins and returns

Data is available to registered users only
Data is available to registered users only
Sign up to get free access to key risk and return factors, detailed company valuation, and analyst forecasts
Sign up to access all the key risk and return factors

Risks

  • Default risk
    Data is available to registered users only
  • Volatility
    Data is available to registered users only
  • Selling difficulty
    Data is available to registered users only
  • Stress test
    Data is available to registered users only
  • Country risks
    Data is available to registered users only
  • Other risks
    Data is available to registered users only
Sign up to access detailed risk analysis

About

Procter & Gamble Health Limited is an Indian entity focused on the production and distribution of pharmaceutical products and chemicals. Its extensive product portfolio includes a variety of over-the-counter (OTC) medications, as well as vitamins, minerals, and dietary supplements. The company's offerings are available under recognized brand names such as Polybion, Neurobion, Evion, Nasivion, Livogen, and Seven Seas. In addition to its domestic operations, Procter & Gamble Health Limited also exports its pharmaceutical goods to several international markets, including Sri Lanka, Nepal, Myanmar, and Maldives. Established in 1967, the company originally operated as Merck Limited, rebranding to Procter & Gamble Health Limited in May 2019. It is headquartered in Mumbai, India, and functions as a subsidiary of Procter & Gamble Overseas India B.V.

Company Valuation

Fairly valued
4/7

From both historical and forecast perspectives, the stock is fairly priced compared to similar stocks. Specifically, the stock is fairly valued on P/E, neutral on EV/EBIT

Data is available to registered users only
Sign up to access detailed valuation

Risks

  • Default risk
    Data is available to registered users only
  • Volatility
    Data is available to registered users only
  • Selling difficulty
    Data is available to registered users only
  • Stress test
    Data is available to registered users only
  • Country risks
    Data is available to registered users only
  • Other risks
    Data is available to registered users only
Sign up to access detailed risk analysis

Trending

25.10.2026 22:01

Solidigm Won't Go Public; New OpenAI Valuation: Key Points on the IPO by October 25

24.10.2026 16:01

Highlights in Small-Cap Stocks: The Merck Deal, the Success of a Hair Loss Pill, and Braze's "Wow Factor"

24.10.2026 13:01

AI investors are already on the brink, a “French kiss” for the euro, and hackers at the gates

24.10.2026 05:04

Hedge funds ramp up bets against euro to highest level since 2020

24.10.2026 04:46

France Avoided a Downgrade by Moody’s After a Week of Crisis

X-channel

Buy

Sell

0 more stocks

Company

  • About
  • Contributors
  • Contacts
  • Legal Information

Social media

  • X (Twitter)
  • LinkedIn

Services

  • Stock Screener
  • Guru Portfolios
  • X (Twitter)
  • LinkedIn
Oninvest© 2026